Body mass index affects imatinib exposure: Real‐world evidence from TDM with adaptive dosingPaul Maroselli, Joseph Ciccolini, Raphaëlle Fanciullino et al.|Fundamental and Clinical Pharmacology|2025Cited by 8
Relationship of body mass index and plasma imatinib levels in CML patients and mitigation of clinical impact using PK-guided dosing strategy.Paul Maroselli, Joseph Ciccolini, Raphaëlle Fanciullino et al.|Journal of Clinical Oncology|2024Cited by 2
Body Mass Index influences Imatinib exposure in CML patients: evidence from TDM with adaptive dosingPaul Maroselli, Joseph Ciccolini, Raphaëlle Fanciullino et al.|HAL (Le Centre pour la Communication Scientifique Directe)|2024Cited by 0
Abstract 4362: Body mass index influences imatinib exposure in CML patients: Evidence fromTDM with adaptive dosing in real-world patientsPaul Maroselli, Joseph Ciccolini, Régis Costello et al.|Cancer Research|2025Cited by 0